Literature DB >> 28359916

Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.

Kai Zhang1, Ya-Wen Wang1, Yan-Yan Wang2, Yu Song1, Jiang Zhu1, Peng-Chao Si3, Rong Ma4.   

Abstract

Accumulating evidence indicates that human circulating microRNAs (miRNAs) could serve as diagnostic and prognostic biomarkers in various cancers. We aimed to explore novel miRNA biomarkers in the blood of breast cancer patients based on miRNA profiling. A miRCURY™ LNA Array was used to identify differentially altered miRNAs in the whole blood of breast cancer patients (n=6) and healthy controls (n=6). Levels of candidate miRNAs were quantified by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in whole blood specimens of 15 breast cancer patients and 13 age-matched healthy control individuals. The miRWalk database was used to predict miRNA targets and the DAVID tool was used to identify significant enrichment pathways. A total of 171 differentially expressed miRNAs were identified by microarray, including 169 upregulated and 2 downregulated miRNAs in breast cancer. Five upregulated miRNAs (miR-30b-5p, miR-96-5p, miR-182-5p, miR-374b-5p, and miR-942-5p) were confirmed by qRT-PCR. The areas under the receiver operating characteristic curve of miR-30b-5p, miR-96-5p, miR-182-5p, miR-374b-5p, and miR-942-5p were 0.9333, 0.7692, 0.7590, 0.8256, and 0.8128, respectively. Importantly, upregulation of these five miRNAs was observed even in patients with very early-stage breast cancer. A total of 855 genes were predicted to be targeted by the five miRNAs, and the one cut domain family member 2 gene (ONECUT2) was a shared target of the five miRNAs. Analysis of publicly available data revealed that these dysregulated miRNAs and the target genes were associated with the survival of breast cancer patients. Furthermore, the five miRNAs were significantly enriched in numerous cancer-related pathways, including "MicroRNAs in cancer", "Pathways in cancer", "FoxO signaling pathway", "Ras signaling pathway", "Rap1 signaling pathway", "MAPK signaling pathway", and "PI3K-Akt signaling pathway". Our data support the potential of the five identified miRNAs as novel biomarkers for the detection of breast cancer, and indicate that they may be involved in breast cancer development and progression.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioinformatics analysis; Biomarkers; Breast cancer; Circulating miRNAs; miRNA microarray

Mesh:

Substances:

Year:  2017        PMID: 28359916     DOI: 10.1016/j.gene.2017.03.038

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  31 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 2.  Biomarkers in Spinal Cord Injury: from Prognosis to Treatment.

Authors:  Leonardo Fonseca Rodrigues; Vivaldo Moura-Neto; Tania Cristina Leite de Sampaio E Spohr
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

Review 3.  Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis.

Authors:  Thu H N Nguyen; Thanh T N Nguyen; Tran T M Nguyen; Le H M Nguyen; Luan H Huynh; Hoang N Phan; Hue T Nguyen
Journal:  Breast Cancer Res Treat       Date:  2022-09-09       Impact factor: 4.624

Review 4.  Emergence of Circulating MicroRNAs in Breast Cancer as Diagnostic and Therapeutic Efficacy Biomarkers.

Authors:  Vaishali Aggarwal; Kumari Priyanka; Hardeep Singh Tuli
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

5.  Pro-inflammatory cytokine polymorphisms in ONECUT2 and HNF4A and primary colorectal carcinoma: a post genome-wide gene-lifestyle interaction study.

Authors:  Su Yon Jung; Jeanette C Papp; Eric M Sobel; Matteo Pellegrini; Herbert Yu; Zuo-Feng Zhang
Journal:  Am J Cancer Res       Date:  2020-09-01       Impact factor: 6.166

Review 6.  MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Authors:  Michele Ghidini; Jens C Hahne; Melissa Frizziero; Gianluca Tomasello; Francesco Trevisani; Andrea Lampis; Rodolfo Passalacqua; Nicola Valeri
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

7.  Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis.

Authors:  Yu Hu; Hayley Dingerdissen; Samir Gupta; Robel Kahsay; Vijay Shanker; Quan Wan; Cheng Yan; Raja Mazumder
Journal:  Comput Biol Med       Date:  2018-10-22       Impact factor: 4.589

8.  Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.

Authors:  Ya-Wen Wang; Weiguo Zhang; Rong Ma
Journal:  Oncol Rep       Date:  2018-01-10       Impact factor: 3.906

9.  MicroRNAs Targeting Caspase-3 and -7 in PANC-1 Cells.

Authors:  Jong Kook Park; Andrea I Doseff; Thomas D Schmittgen
Journal:  Int J Mol Sci       Date:  2018-04-16       Impact factor: 5.923

10.  Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting ONECUT2.

Authors:  Meng Shen; Chuan Dong; Xianhui Ruan; Wei Yan; Minghui Cao; Donald Pizzo; Xiwei Wu; Lin Yang; Liang Liu; Xiubao Ren; Shizhen Emily Wang
Journal:  Cancer Res       Date:  2019-05-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.